RNS Number : 8920B
Hikma Pharmaceuticals Plc
04 February 2020

London, February 4, 2020 - Hikma Pharmaceuticals PLC (Hikma, Group / LSE: HIK / NASDAQ Dubai: HIK / OTC: HKMPY) (rated Ba1/stable Moody's and BB+/positive S&P), will announce its preliminary financial results for the year ended 31 December 2019 on Thursday 27 February 2020.

A presentation and webcast for analysts will be held on 27 February 2020 at 9:30am GMT, for further information about the meeting, please get in contact with Tiina Lugmayer -


To join via conference call please dial:

United Kingdom 0800 640 6441 

United Kingdom (local) 020 3936 2999 

All other locations +44 20 3936 2999


Access code: 442936

The results presentation and a webcast recording of the event will be available on the Company's website at or

Playback facility:

A playback of the conference call will be available up to six months after the presentation.

UK: 020 3936 3001

USA: 1 845 709 8569

All other locations: +44 20 3936 3001


Access code: 169303




- ENDS -



Hikma Pharmaceuticals PLC

Susan Ringdal
EVP, Strategic Planning and Global Affairs

+44 (0)20 7399 2760/ +44 7776 477050



FTI Consulting

Ben Atwell

+44 (0)20 3727 1000




About Hikma
Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,400 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit:



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit